Summary of 2018 American Society of Clinical Oncologist's Annual Meeting- Prostate Cancer starts at 35:00

[tallguy2]

I listened to the summary, which is available here:

cancercare.org/connect_work...

You can fast-forward to 35:00 minutes to hear the summary for prostate cancer. There are three topics covered in this section.

1. Novel Imaging

2. Biomarkers

3. PARP Inhibitors (Lynparza, Rubraca, Zejula) combined with abiraterone

This last topic is what I will address with my oncologist this Friday. Most of this is not FDA approved.

[snoraste]

would love to hear what your MO says about Abi+PARP if you could post

[tallguy2 in reply to snoraste]

Will do. On 9/14/2018 I was released by my oncologist, having completed 6 rounds of Taxotere. PSA= 0.13. I am promised a call by the end of the month recommending which clinical trials, if any, are appropriate for me. I specifically asked about those involving PARP inhibitors + abiraterone. I stated that I will travel anywhere. I will post.